Thursday, Moderna ( MRNA ) Inc unveiled key updates at its annual R&D Day, spotlighting its mRNA-based pipeline and revised financial plans.

CEO Stéphane Bancel emphasized the company’s success in respiratory vaccines, stating that Moderna ( MRNA ) now has five respiratory vaccines with positive Phase 3 results and expects three approvals this year. The company is also focusing on five non-respiratory products, aiming for approvals by 2027.

Also Read: Moderna’s Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows.

Faced with commercial challenges, Moderna ( MRNA ) is adopting a more selective approach to R&D investments. The company anticipates maintaining substantial R&D investment, especially in oncology and rare diseases, while pacing other expenditures.

The company plans to reduce annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products.

The company expects R&D expenses to fall from $4.8 billion in 2024E to $3.6 billion-$3.8 billion in 2027.

This strategy, expanding its portfolio into oncology and rare diseases, positions Moderna ( MRNA ) to deliver ten product approvals within the next three years.

Financially, Moderna ( MRNA ) expects its respiratory franchise to become profitable by 2024 and projects revenues of $2.5 to $3.5 billion by 2025 versus consensus of $3.74 billion. For 2026-2028, the company expects a compounded annual growth rate of more than 25%, driven by new product launches.

Moderna ( MRNA ) also expects its year-end cash and investments for 2025 to reach approximately $6 billion.

The company aims to break even on an operating cash cost basis—excluding stock-based compensation, depreciation, and amortization—by 2028, targeting $6 billion in revenue.

Moderna ( MRNA ) has assured stakeholders that it possesses sufficient capital to fund its operations and reach this break-even point without raising additional equity.

Price Action: MRNA stock is down 17.60% at $65.54 at the last check Thursday.

Read Next:

European Central Bank Cuts Key Interest Rates As Inflation Cools.